Substitution and reincarceration - Elements for an analysis of a complex relationship


Substitution and reincarceration

Tendances n° 57, OFDT, 4 p.
December 2007

The study was carried out in remand centres. The patients described in the survey are consequently prisoners awaiting trial and convicts whose remaining sentence is less than one year or who are awaiting a transfer to an établissement pour peine (penal institutions, detention centres, etc. for convicted prisoners). It has made it possible to describe the general profile of opioid-dependent prisoners but also to carry out a prospective study, the first of its kind in France, over a period of 24 months in order to assess the level of reincarceration among prisoners having received OST compared to a control group of prisoners who did not receive an OST when beginning their period of detention. This analysis made it possible to identify the various factors associated with reincarceration. Finally, the survey has sought to highlight the differences in profile between those people receiving an OST when their period in detention began (for the first time or otherwise) and those whose substitution was interrupted or not renewed when they were incarcerated, which are both useful factors as decision-making aids, when it comes to identifying the predictive signs and indicators that a subject is about to abandon treatment (or anticipating abandonment of treatment).

Authors :
Ivana Obradovic, Jean-Noël Marzo, Michel Rotily, Fadi Meroueh, Pierre-Yves Robert, Bruno Vanrenterghem, Frédérique Seltz, Patrick Vogt … and the RECAMS group

Download the PDF file (131 Ko)

Drugs in Europe

2016 EMCDDA European Drug Report

- Drug facts, figures and analyses: across Europe and by country
- Latest trends and legal, political and social responses
- Selected issues: Vulnerable groups of young people; National drug-related research in Europe; Towards a better understanding of drug-related public expenditure in Europe

Country situation summaries

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) website has a concise overview for each EU Member State on their national drug situation, as well as legal texts in their original formats, an indispensable tool for monitoring and analysing legislative developments in the Member States.

The European Union and the drug phenomenon

The European Union & the drug phenomenon : Frequently asked questions , joint publication between the EMCDDA and the European Commission, october 2010, 12 p.